Rojas-Martínez R, Escamilla-Nuñez C, Castro-Porras L, Gómez-Velasco D, Romero-Martínez M, Aguilar-Salinas CA

Language: English
References: 31
Page: 277-287
PDF size: 294.90 Kb.

ABSTRACT

Objective. To inform the prevalence of cardiovascular risk factors and vascular complications in Mexican adults with early- and late-onset diabetes. Materials and methods. Information from adults aged 20 years and over participating in the Encuesta Nacional de Salud y Nutrición 2018 was used. To compare variables, chi-square tests and Student’s t-test were performed. Multiple logistic regression models of having micro and macrovascular complications were obtained. Results. Prevalence of diagnosed hypertension on early and late diabetes onset were 37.8 and 51.5%, dyslipidemia 42.6 and 43.8%, tobacco consumption 13.5 and 10.2% and obesity 46.5 and 43.0%, respectively. The average time since diagnosis was 16.9 years for those with early-onset diabetes and 8.9 years for those with late-onset. Peripheral vascular disease in the group with early-onset diabetes was 13.5% (20.2% in those with 10 years and more of diabetes duration), and 5.3% in late-onset diabetes group (7.2% in those with 10 years and more of diabetes duration). Conclusion. Adults with earlyonset diabetes presented higher proportion of macrovascular complications, probably due to the longer exposure time to hyperglycemia. Patients with early-onset diabetes require intensive treatment to prevent cardiovascular events. Patients with late-onset diabetes require management of age-related comorbidities as hypertension and dyslipidemia.

REFERENCES

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes:Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53. https://doi.org/10.2337/diacare.27.5.1047

2. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, etal. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalenceestimates for 2021 and projections for 2045. Diabetes Res ClinPract. 2022;183. https://doi.org/10.1016/j.diabres.2021.109119

3. Instituto Nacional de Estadística y Geografía. Estadísticas a propósitodel día mundial de la diabetes (14 de noviembre). Comunicado de prensaNúm. 645/21. Mexico: INEGI, 2021 [cited August 2023]. Available from:https://www.inegi.org.mx/contenidos/saladeprensa/aproposito/2021/EAP_Diabetes2021.pdf

4. Basto-Abreu AC, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA,De la Cruz-Góngora VV, Rivera-Dommarco J, et al. Prevalence of diabetesand glycemic control in Mexico: national results from 2018 and 2020. SaludPublica Mex. 2021;63(6):725-33. https://doi.org/10.21149/12842

5. Song SH. Early-onset type 2 diabetes mellitus: a condition with elevatedcardiovascular risk? Br J Diabetes Vasc Dis. 2008;8(2):61-5. https://doi.org/10.1177/14746514080080020201

6. Huo X, Gao L, Guo L, Xu E, Wang W, Zhi X, et al. Risk of non-fatalcardiovascular diseases in early-onset versus late-onset type 2 diabetes inChina: a cross-sectional study. Lancet Diabetes Endocrinol. 2016;4(2):115-24. https://doi.org/10.1016/S2213-8587(15)00508-2

7. Chowdhury TA, Lasker SS. Complications and cardiovascular risk factorsin South Asians and Europeans with early-onset type 2 diabetes. QJM.2002;95(4):241-6. https://doi.org/10.1093/qjmed/95.4.241

8. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-RodriguezM, Gale CP, et al. Type 2 diabetes and incidence of cardiovascular diseases:a cohort study in 1.9 million people. Lancet Diabetes Endocrinol.2015;3(2):105-13. https://doi.org/10.1016/S2213-8587(14)70219-0

9. Amiel SA, Aschner P, Childs B, Cryer PE, De Galan BE, Frier BM, etal. Hypoglycaemia, cardiovascular disease, and mortality in diabetes:epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol.2019;7(5):385-96. https://doi.org/10.1016/S2213-8587(18)30315-2

10. Romero-Martínez M, Shamah-Levy T, Vielma-Orozco E, Heredia-Hernández O, Mojica-Cuevas J, Cuevas-Nasu L, et al. Encuesta Nacional deSalud y Nutrición 2018-19: metodología y perspectivas. Salud Publica Mex.2019;61(6):917-23. https://doi.org/10.21149/11095

11. British Cardiac Society, British Hypertension Society, Diabetes UK,HEART UK, Primary Care Cardiovascular Society, The Stroke Association.JBS 2: Joint British Societies’ guidelines on prevention of cardiovasculardisease in clinical practice. Heart. 2005;91(suppl 5):v1-v52. https://doi.org/10.1136/hrt.2005.079988

12. World Health Organization. Obesity and overweight. Key facts. Geneva:WHO, 2021 [cited August 2023]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

13. North American Association for the Study of Obesity, NationalHeart, Lung, Blood Institute, & NHLBI Obesity Education Initiative. Thepractical guide: identification, evaluation, and treatment of overweightand obesity in adults. United States: National Institutes of Health,National Heart, Lung, and Blood Institute, NHLBI Obesity EducationInitiative, North American Association for the Study of Obesity, 2000[cited August 2023]. Available from: https://www.nhlbi.nih.gov/files/docs/guidelines/prctgd_c.pdf

14. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA,et al. Harmonizing the metabolic syndrome: a joint interim statement of theInternational Diabetes Federation Task Force on Epidemiology and Prevention;National Heart, Lung, and Blood Institute; American Heart Association;World Heart Federation; International Atherosclerosis Society; and InternationalAssociation for the Study of Obesity. Circulation. 2009;120(16):1640-5.https://doi.org/10.1161/CIRCULATIONAHA.109.192644

15. IPAQ Research Committee. Guidelines for data processing and analysisof the International Physical Activity Questionnaire (IPAQ)-short andlong forms. IPAQ, 2005 [cited August 2023]. Available from: https://www.researchgate.net/file.PostFileLoader.html?id=5641f4c36143250eac8b45b7&assetKey=AS%3A294237418606593%401447163075131

16. Salinas-Rodríguez A, Manrique-Espinoza B, Acosta-Castillo GI,Franco-Núñez A, Rosas-Carrasco O, Gutiérrez-Robledo LM, Sosa-OrtizAL. Validation of a cutoff point for the short version of the DepressionScale of the Center for Epidemiologic Studies in older Mexican adults.Salud Publica Mex. 2014;56(3):279-85. https://doi.org/10.21149/spm.v56i3.7346

17. Ueda P, Woodward M, Lu Y, Hajifathalian K, Al-Wotayan R, Aguilar-Salinas CA, et al. Laboratory-based and office-based risk scores andcharts to predict 10-year risk of cardiovascular disease in 182 countries:a pooled analysis of prospective cohorts and health surveys. LancetDiabetes Endocrinol. 2017;5(3):196-213. https://doi.org/10.1016/S2213-8587(17)30015-3

18. Gunathilake W, Song S, Sridharan S, Fernando DJ, Idris I. Cardiovascularand metabolic risk profiles in young and old patients with type 2 diabetes.QJM Int J Med. 2010;103(11):881-4. https://doi.org/10.1093/qjmed/hcq135

19. Yokoyama H, Okudaira M, Otani T, Takaike H, Miura J, Saeki A, et al.Existence of early-onset NIDDM Japanese demonstrating severe diabeticcomplications. Diabetes Care. 1997;20(5):844-7. https://doi.org/10.2337/diacare.20.5.844

20. Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, healthburden and effective interventions for elevated blood pressure and hypertension.Nat Rev Cardiol. 2021;18(11):785-802. https://doi.org/10.1038/s41569-021-00559-8

21. Nanayakkara N, Pease AJ, Ranasinha S, Wischer N, AndrikopoulosB, De Courten B, Zoungas S. Younger people with Type 2 diabetes havepoorer self-care practices compared with older people: results from theAustralian National Diabetes Audit. Diabet Med. 2018;35(8):1087-95.https://doi.org/10.1111/dme.13660

22. Hamaty M, Lamberti M, Sowers JR. Diabetic vascular disease andhypertension. Curr Opin Cardiol. 1998;13(5):298-303. https://doi.org/10.1097/00001573-199809000-00002

23. Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovasculardisease: clinical insights and vascular mechanisms. Can J Cardiol.2018;34(5):575-84. https://doi.org/10.1016/j.cjca.2017.12.005

24. Olaiz G, Rojas R, Barquera S, Shamah-Levy T, Aguilar C, Cravioto P, etal. Encuesta Nacional de Salud 2000. Tomo 2. La salud de los adultos. Cuernavaca,Morelos, México: Instituto Nacional de Salud Pública, 2003 [citedAugust 2023]. Available from: https://ensanut.insp.mx/encuestas/ensa2000/doctos/informes/ENSA_tomo2.pdf

25. Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, Villalpando-Hernández S, Franco A, Cuevas-Nasu L, et al. Encuesta Nacional de Saludy Nutrición 2012. Resultados nacionales. 2.a ed. Cuernavaca, México:Instituto Nacional de Salud Pública, 2013 [cited August 2023]. Availablefrom: https://ensanut.insp.mx/encuestas/ensanut2012/informes.php

26. Shamah-Levy T, Vielma-Orozco E, Heredia-Hernández O, Romero-Martínez M, Mojica-Cuevas J, Cuevas-Nasu L, et al. Encuesta Nacional deSalud y Nutrición 2018-19: Resultados Nacionales. Cuernavaca, México:Instituto Nacional de Salud Pública, 2020 [cited August 2023]. Availablefrom: https://ensanut.insp.mx/encuestas/ensanut2018/informes.php

27. Barceló A, Aedo C, Rajpathak S, Robles S. The cost of diabetes in LatinAmerica and the Caribbean. Bull World Health Organ. 2003;81(1):19-27[cited August 2023]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2572319/pdf/12640472.pdf

28. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovasculardisease in type 2 diabetes: a systematic literature review of scientificevidence from across the world in 2007-2017. Cardiovascular Diabetol.2018;17(1):1-19. https://doi.org/10.1186/s12933-018-0728-6

29. Diario Oficial de la Federación. Norma Oficial Mexicana NOM-015-SSA2-2010, para la prevención, tratamiento y control de la diabetes mellitus.Mexico: DOF, 2010 [cited August 2023]. Available from: http://www.dof.gob.mx/normasOficiales/4215/salud/salud.htm

30. Secretaría de Salud. Prevención, diagnóstico, metas de control ambulatorioy referencia oportuna de la diabetes mellitus tipo 2 en el primer nivel deatención. Guía de referencia rápida. Guía de práctica clínica. Mexico: CentroNacional de Excelencia Tecnológica en Salud, 2019 [cited August 2023]. Availablefrom: http://www.cenetec-difusion.com/CMGPC/GPC-SS-093-19/RR.pdf

31. Pavía AA, Aguilar C, Alexanderson E, Ahumada M, Alcocer M, ArenasLR, et al. Consenso de la Sociedad Mexicana de Cardiología en el diagnósticoy tratamiento de las dislipidemias y aterosclerosis. Med Int Mex.2020;36(3):390-413. https://doi.org/10.24245/mim.v36i3.3671